A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
Launched by ASLAN PHARMACEUTICALS · Mar 10, 2017
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Study I: Subjects with a solid tumour (excluding haematologic tumors) in advanced or metastatic stage
- • Study II: Subjects with advanced (unresectable) or metastatic biliary tract cancer (IHCC, EHCC, gallbladder cancer or ampullary carcinoma)
- Exclusion Criteria:
- • Subjects with concurrent multiple primary cancers.
- • Subjects with a history of (non-infectious) pneumonitis that required steroids or current pneumonitis, or with a history of interstitial lung disease or current interstitial lung disease
- • Subjects receiving proton pump inhibitors for established, symptomatic gastro-duodenal ulceration or gastroesophageal reflux disease (including the preventive use)
About Aslan Pharmaceuticals
Aslan Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with cancer and autoimmune diseases. The company is dedicated to advancing a diverse pipeline of targeted therapies that address unmet medical needs, leveraging cutting-edge scientific research and strategic collaborations. With a commitment to improving patient outcomes, Aslan Pharmaceuticals aims to bring transformative treatments to market through rigorous clinical trials and a patient-centric approach to drug development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials